Khalid Yusoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/320263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE) Tj ETQq1	1 0.784314 13.7	rgBT_/Qverlo
2	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
3	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, The, 2016, 388, 761-775.	13.7	1,414
4	Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet, The, 2015, 386, 266-273.	13.7	1,295
5	Modifiable risk factors, cardiovascular disease, and mortality in 155â€^722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet, The, 2020, 395, 795-808.	13.7	935
6	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, The, 2011, 378, 1231-1243.	13.7	803
7	Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events. New England Journal of Medicine, 2014, 371, 612-623.	27.0	725
8	Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. New England Journal of Medicine, 2014, 371, 818-827.	27.0	679
9	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	27.0	641
10	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	27.0	526
11	Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet, The, 2017, 390, 2037-2049.	13.7	446
12	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
13	Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet, The, 2016, 388, 465-475.	13.7	381
14	Importance of lead selection in QT interval measurement. American Journal of Cardiology, 1988, 61, 83-87.	1.6	340
15	Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. The Lancet Global Health, 2019, 7, e748-e760.	6.3	340
16	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	27.0	299
17	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2019, 157, 682-691.e2.	1.3	299
18	Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet, The, 2018, 392, 2288-2297.	13.7	295

#	Article	IF	CITATIONS
19	Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet, The, 2016, 387, 61-69.	13.7	272
20	Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet Global Health, 2017, 5, e665-e672.	6.3	247
21	Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet, The, 2018, 392, 496-506.	13.7	243
22	Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. European Heart Journal, 2019, 40, 1620-1629.	2.2	208
23	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. Journal of the American College of Cardiology, 2012, 59, 74-83.	2.8	164
24	Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 216-228.	27.0	163
25	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124, 1727-1736.	1.6	156
26	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. Diabetes Care, 2016, 39, 780-787.	8.6	138
27	A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE) Tj ETQq1 I	l 0,784314 13.7	1 rgBT /Ove
28	Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health, The, 2017, 2, e411-e419.	10.0	134
29	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	1.7	133
30	Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. New England Journal of Medicine, 2021, 384, 1312-1322.	27.0	124
31	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes and Endocrinology,the, 2018, 6, 798-808.	11.4	116
32	Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. American Heart Journal, 2013, 166, 636-646.e4.	2.7	113
33	Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. International Journal of Cardiology, 2016, 204, 133-141.	1.7	108
34	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, 157, 403-412.e5.	1.3	108
35	Associations of outdoor fine particulate air pollution and cardiovascular disease in 157â€^436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet Planetary Health, The, 2020, 4, e235-e245.	11.4	106
36	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet, The, 2018, 391, 2019-2027.	13.7	96

#	Article	IF	CITATIONS
37	The household economic burden of non-communicable diseases in 18 countries. BMJ Global Health, 2020, 5, e002040.	4.7	90
38	Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. BMJ: British Medical Journal, 2019, 364, 1772.	2.3	85
39	Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. The Lancet Global Health, 2018, 6, e292-e301.	6.3	73
40	Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. American Journal of Clinical Nutrition, 2020, 111, 795-803.	4.7	71
41	Prevalence, awareness, treatment, control and socio demographic determinants of hypertension in Malaysian adults. BMC Public Health, 2016, 16, 351.	2.9	70
42	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. JAMA Internal Medicine, 2021, 181, 631.	5.1	68
43	Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. International Journal for Equity in Health, 2016, 15, 199.	3.5	67
44	Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach. BMC Health Services Research, 2015, 15, 254.	2.2	65
45	Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries. BMJ Open Diabetes Research and Care, 2020, 8, e000826.	2.8	57
46	Dose Dependent Elevation of Plasma Tocotrienol Levels and Its Effect on Arterial Compliance, Plasma Total Antioxidant Status, and Lipid Profile in Healthy Humans Supplemented with Tocotrienol Rich Vitamin E. Journal of Nutritional Science and Vitaminology, 2006, 52, 473-478.	0.6	56
47	Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries. Cardiology Clinics, 2017, 35, 99-115.	2.2	56
48	JIS Definition Identified More Malaysian Adults with Metabolic Syndrome Compared to the NCEP-ATP III and IDF Criteria. BioMed Research International, 2013, 2013, 1-10.	1.9	54
49	Long-term exposure to outdoor and household air pollution and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) study. Environmental Pollution, 2020, 262, 114197.	7.5	47
50	Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries. BMJ Open, 2017, 7, e013817.	1.9	44
51	Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Global Health, 2020, 5, e002640.	4.7	41
52	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. JAMA Cardiology, 2021, 6, 1042.	6.1	35
53	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. Diabetes Care, 2020, 43, 3094-3101.	8.6	32
54	Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF). American Heart Journal, 2015, 170, 627-634.e1.	2.7	29

#	Article	IF	CITATIONS
55	The environmental profile of a community's health: a cross-sectional study on tobacco marketing in 16 countries. Bulletin of the World Health Organization, 2015, 93, 851-861G.	3.3	29
56	Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35–70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study. Injury Prevention, 2016, 22, 92-98.	2.4	28
57	Prevalence of atrial fibrillation in the Malaysian communities. Heart Asia, 2016, 8, 62-66.	1.1	25
58	Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. Heart, 2021, 107, 282-289.	2.9	25
59	Behaviour change strategies for reducing blood pressure-related disease burden: findings from a global implementation research programme. Implementation Science, 2015, 10, 158.	6.9	24
60	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	1.7	24
61	The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. American Heart Journal, 2018, 206, 72-79.	2.7	24
62	Systematic Pharmacogenomics Analysis of a Malay Whole Genome: Proof of Concept for Personalized Medicine. PLoS ONE, 2013, 8, e71554.	2.5	22
63	Cardiovascular disease risk factors and socioeconomic variables in a nation undergoing epidemiologic transition. BMC Public Health, 2013, 13, 886.	2.9	20
64	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	2.2	18
65	High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: the REDISCOVER study. BMC Cardiovascular Disorders, 2021, 21, 149.	1.7	17
66	Current Status of Coronary Risk Factors Among Rural Malays in Malaysia. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 17-23.	2.8	16
67	Responsive and Equitable Health Systems—Partnership on Non-Communicable Diseases (RESPOND) study: a mixed-methods, longitudinal, observational study on treatment seeking for hypertension in Malaysia and the Philippines. BMJ Open, 2018, 8, e024000.	1.9	15
68	Development, Testing, and Implementation of a Training Curriculum for Nonphysician Health Workers to Reduce Cardiovascular Disease. Global Heart, 2018, 13, 93.	2.3	15
69	Risk perception of cardiovascular diseases among individuals with hypertension in rural Malaysia. Heart Asia, 2017, 9, e010864.	1.1	14
70	Vitamin E in cardiovascular disease: has the die been cast?. Asia Pacific Journal of Clinical Nutrition, 2002, 11, S443-S447.	0.4	13
71	Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension. Hereditas, 2019, 156, 1.	1.4	13
72	In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. PLoS ONE, 2010, 5, e13694.	2.5	12

#	Article	IF	CITATIONS
73	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 17-23.	1.5	11
74	The impact of physical activity on cumulative cardiovascular disease risk factors among Malaysian adults. BMC Public Health, 2015, 15, 1242.	2.9	11
75	Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study. American Heart Journal, 2018, 203, 57-66.	2.7	11
76	Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study. Sleep Medicine, 2021, 80, 265-272.	1.6	11
77	Developing consensus measures for global programs: lessons from the Global Alliance for Chronic Diseases Hypertension research program. Globalization and Health, 2017, 13, 17.	4.9	10
78	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke, 2021, 52, 2494-2501.	2.0	10
79	Rare Copy Number Variants Identified Suggest the Regulating Pathways in Hypertension-Related Left Ventricular Hypertrophy. PLoS ONE, 2016, 11, e0148755.	2.5	8
80	The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges. Molecular Cytogenetics, 2013, 6, 8.	0.9	7
81	Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case–Control Study. American Journal of Hypertension, 2021, 34, 414-425.	2.0	6
82	Increased serum levels of soluble ICAM-1 and IL-6 reflect endothelial dysfunction in statin-treated patients with hypercholesterolaemia. Atherosclerosis, 2004, 174, 191-192.	0.8	5
83	Observational study of the status of coronary risk biomarkers among Negritos with metabolic syndrome in the east coast of Malaysia. BMJ Open, 2018, 8, e021580.	1.9	5
84	Classification of heart sound based on multipoint auscultation system. , 2013, , .		4
85	Two-channel data acquisition unit for heart sound analysis. , 2005, , .		2
86	PS 15-01 Mismatch between actual risk and perceived risk for cardiovascular disease among elderly in a rural population of Malaysia. Journal of Hypertension, 2016, 34, e459.	0.5	2
87	Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study. Neuroepidemiology, 2021, 55, 206-215.	2.3	2
88	Hypertension control: lessons from Malaysia, a upper-middle-income country. Journal of Cardiology & Current Research, 2021, 14, 69-73.	0.1	2
89	Patient pathways for cardiovascular diseases in Malaysia and the Philippines: a systematic review. Wellcome Open Research, 0, 6, 43.	1.8	0
90	IMPAIRED GLUCOSE TOLERANCE AND IMPAIRED FASTING GLUCOSE HAVE DIFFERENT ASSOCIATED RISK FACTOR PROFILES. Journal of Hypertension, 2004, 22, S50.	0.5	0